Application specialist italy
Pubblicato il 04-08-2026 - Sakura Finetek Italy in Italia
Why Sakura? When it comes to diagnosing cancer, there's no time to wait What we do: We empower pathology professionals all over the world by providing integrated solutions to deliver accurate & fast diagnoses of cancer, to optimize treatment success for each life we touch The opportunity: The Application Specialist (1st Line) provides operational, application and quality control support to customers all across the North region of Italy. The role includes supporting customers in this region through user training, troubleshooting, system installations and quality-related activities. The Application Specialist ensures that Sakura solutions are used correctly and according to procedures. The specialist works independently on non-complex projects, including activities within the North of Italy, in line with Sakura's way of working. For some projects, a structured and well-considered approach may be required. We perfectly match if you have: Relevant degree in Laboratory Sciences or equivalent background. Minimum 3 years of experience in histopathology is strongly recommended.
Strong training and communication skills. Strong analytical and problem‐solving capabilities. Hands‐on, practical mentality with high customer focus. Ability to work independently and in multidisciplinary, cross‐country teams. and you: Are fluent in Italian language and proficient in English; additional European languages are a plus. Are willing to travel at least 50% of the time. We offer you: An attractive salary package, including a premio scheme. A company car, mobile phone, tablet & laptop. And last but not least, a great job opportunity where you have full ownership of your work, recognition of your achievements and professional development opportunities. The invitation: Our culture is friendly and open. We believe that the development of our people enables the company's growth. By joining us, you will be part of: An inspiring community with a mission that matters ''advancing cancer diagnostics'